loading page

Anti-Amyloid-β Monoclonal Antibodies against Alzheimer’s disease may be a potential breakthrough for cataract treatment
  • Ali Rahmani,
  • Maedeh Dahaghin
Ali Rahmani
Tehran University of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Maedeh Dahaghin
Tehran University of Medical Sciences
Author Profile

Abstract

Cataracts are considered the underlying cause of blindness globally. When the average age of the earth’s population is on the rise, cataract-induced blindness and visual dysfunction will increase dramatically. (1) Currently, the only viable treatment for cataracts is surgery, including removing the opaque lens and replacing it with an artificial one which has a huge impact on improving the patient’s quality of life. Undoubtedly, cataracts have far-reaching repercussions for countries in terms of social and economic burdens, for example, the increasing rate of automobile accidents due to reduced visual acuity. (2) Nonetheless, due to the lack of facilities, ophthalmologists, and funds, surgery is not a choice in developing countries. (3) It should be noted that posterior capsular opacification is a common complication of cataracts, and sometimes, a second intervention is necessary. (4)This research has thrown up many questions in need of further investigation to find medications that restore full transparency of the lens.